SEC Form DEFA14A filed by Zentalis Pharmaceuticals Inc.
$ZNTL
Biotechnology: Pharmaceutical Preparations
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE 14A
Schedule 14A Information
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. 1)
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
| ☐ | Preliminary Proxy Statement | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| ☐ | Definitive Proxy Statement | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| ☒ | Definitive Additional Materials | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| ☐ | Soliciting Material under §240.14a-12 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Zentalis Pharmaceuticals, Inc.
(Name of Registrant as Specified In Its Charter)
n/a
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
| ☒ | No fee required | ||||||||||||||||||||||
| ☐ | Fee paid previously with preliminary materials | ||||||||||||||||
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 | ||||||||||||||||
ZENTALIS PHARMACEUTICALS, INC.
AMENDMENT TO THE DEFINITIVE PROXY STATEMENT
FOR THE ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON JUNE 17, 2025
May 23, 2025
Dear Zentalis Stockholder,
The proxy statement for the 2025 Annual Meeting of Stockholders, or the Proxy Statement, of Zentalis Pharmaceuticals, Inc., a Delaware corporation, or the Company, to be held on June 17, 2025, or the Annual Meeting, was filed with the U.S. Securities and Exchange Commission on April 30, 2025. This amendment to the Proxy Statement, or the Proxy Amendment, is being filed solely to update the table below showing the composition of the committees of the Board of Directors of the Company on page 20 of the Proxy Statement, or the Committee Composition Table, to correct a typographical error. The Committee Composition Table in the Proxy Statement indicated that the membership of the Nominating and Corporate Governance Committee, or the Nominating Committee, was Jan Skvarka (Chairperson), Karan Takhar and Scott Myers; however, the membership of the Nominating Committee is Dr. Skvarka (Chairperson), Mr. Takhar and Luke Walker, as set forth in the updated table below.
| Name | Audit | Compensation | Nominating and Corporate Governance | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Scott Myers†* | M | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| David Johnson | M | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Enoch Kariuki, Pharm.D. | CH | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Jan Skvarka, Ph.D. | M | CH | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Karan Takhar* | CH | M | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Luke Walker, M.D.* | M | M | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
* Nominated for election at the Annual Meeting. See Proposal 1 in the Proxy Statement.
† Chairperson of the Board
CH Chairperson of the Committee
M Member of the Committee
Apart from the update to the Committee Composition Table, no other changes have been made to the Proxy Statement or to the matters to be considered at the Annual Meeting, and this Proxy Amendment does not otherwise modify, amend, supplement, or affect the Proxy Statement. Stockholders do not need to take any action if they have already voted their shares for the Annual Meeting.
Sincerely,
/s/ Julie Eastland
Julie Eastland
President, Chief Executive Officer and Director